Table 1 Summary of FDA-approved immune checkpoint inhibitors
Agent | Manufacturer | Target | Molecular type | FDA-Approved Application | Trail(s) based |
|---|---|---|---|---|---|
Pembrolizumab (Keytruda) | Merck & Co | PD-1 | An IgG4 kappa immunoglobulin | Melanoma | KEYNOTE-002 (NCT01704287) KEYNOTE-006 (NCT01866319) KEYNOTE‑054 (NCT02362594) |
NSCLC | KEYNOTE‑042 (NCT02220894) KEYNOTE-189 (NCT02578680) KEYNOTE-407 (NCT03875092) KEYNOTE-021 (NCT02039674) KEYNOTE-010 (NCT01905657) | ||||
HNSCC | KEYNOTE-048 (NCT02358031) KEYNOTE-012 (NCT01848834) | ||||
cHL | KEYNOTE-204 (NCT02684292) KEYNOTE-087 (NCT02453594) | ||||
PMBCL | KEYNOTE-170 (NCT02576990) | ||||
Urothelial carcinoma | KEYNOTE-052 (NCT02335424) KEYNOTE-045 (NCT02256436) | ||||
Colorectal cancer | KEYNOTE-177 (NCT02563002) | ||||
Gastric cancer | KEYNOTE-811 (NCT03615326) | ||||
Esophageal cancer | KEYNOTE-590 (NCT03881111) KEYNOTE-181 (NCT03933449) | ||||
Cervical cancer | KEYNOTE-826 (NCT03635567) KEYNOTE 158 (NCT02628067) | ||||
HCC | KEYNOTE 224 (NCT02702414) | ||||
MCC | KEYNOTE-017 (NCT02267603) | ||||
RCC | KEYNOTE-426 (NCT02853331) KEYNOTE-581 (NCT02811861) KEYNOTE‑564 (NCT03142334) | ||||
Endometrial carcinoma | KEYNOTE 158 (NCT02628067) KEYNOTE-775 (NCT03517449) | ||||
TMB-high cancer | KEYNOTE 158 (NCT02628067) | ||||
cSCC | KEYNOTE-629 (NCT03284424) | ||||
TNBC | KEYNOTE-522 (NCT03036488) KEYNOTE-355 (NCT02819518) | ||||
Nivolumab (Opdivo) | Bristol-Myers Squibb | PD-1 | A human IgG4 monoclonal antibody | Melanoma | CHECKMATE-037 (NCT01721746) CHECKMATE-066 (NCT01721772) CHECKMATE-067 (NCT01844505) CHECKMATE-238 (NCT02388906) |
NSCLC | CHECKMATE-227 (NCT02477826) CHECKMATE-816 (NCT02998528) CHECKMATE-9LA (NCT03215706) CHECKMATE-057 (NCT01673867) | ||||
Malignant pleural mesotheliom | CHECKMATE-743 (NCT02899299) | ||||
RCC | CHECKMATE-214 (NCT02231749) CHECKMATE-9ER (NCT03141177) CHECKMATE-025 (NCT01668784) | ||||
cHL | CHECKMATE-039(NCT01592370) | ||||
SCCHN | CHECKMATE-141(NCT02105636) | ||||
Urothelial carcinoma | CHECKMATE-274 (NCT02632409) CHECKMATE-275(NCT02387996) | ||||
Colorectal cancer | CHECKMATE-142 (NCT02060188) | ||||
HCC | CHECKMATE -040 (NCT01658878) | ||||
Esophageal cancer | CHECKMATE-577 (NCT02743494) CHECKMATE-648 (NCT03143153) CHECKMATE-649 (NCT02872116) ATTRACTION-3 (NCT02569242) | ||||
Cemiplimab(Libtayo) | Regeneron Pharmaceuticals | PD-1 | A recombinant human IgG4 monoclonal antibody | CSCC | Study 1423 (NCT02383212) Study 1540 (NCT02760498) |
Basal cell carcinoma | Study 1620 (NCT03132636) | ||||
NSCLC | Study 1624 (NCT03088540) | ||||
Dostarlimab (Jemperli) | GlaxoSmithKline | PD-1 | An investigational humanized IgG4 monoclonal antibody | Endometrial cancer | GARNET (NCT02715284) |
solid tumors | GARNET (NCT02715284), | ||||
Atezolizumab (Tecentriq) | Genentech | PD-L1 | An Fc-engineered, humanized, non-glycosylated IgG1 kappa immunoglobulin | HCC | IMbrave150(NCT03434379) |
Urothelial carcinoma | IMvigor210 (NCT02108652) IMvigor130 (NCT02807636) | ||||
NSCLC | IMvigor010 (NCT02486718) IMpower110 (NCT02409342) IMpower150 (NCT02366143) IMpower130 (NCT02367781) OAK(NCT02008227) | ||||
SCLC | IMpower133(NCT02763579) | ||||
Melanoma | IMspire150 (NCT02908672) | ||||
Durvalumab (Imfinzi) | AstraZeneca | PD-L1 | A human IgG1 kappa monoclonal antibody | SCLC | CASPIAN(NCT03043872) |
NSCLC | PACIFIC (NCT02125461) | ||||
Urothelial carcinoma | Study1108(NCT01693562) | ||||
Avelumab(Bavencio) | EMD Serono | PD-L1 | A human IgG1 lambda monoclonal antibody | RCC | JAVELIN Renal 101(NCT02684006) |
Urothelial carcinoma | JAVELIN Solid Tumor (NCT01772004) | ||||
MCC | JAVELIN Merkel 200 (NCT02155647) | ||||
Ipilimumab (Yervoy) | Bristol-Myers Squibb | CTL-4 | An IgG1 kappa immunoglobulin | HCC | CHECKMATE-040 (NCT01658878) |
Colorectal cancer | CHECKMATE-142 (NCT02060188) | ||||
RCC | CHECKMATE-214 (NCT02231749) | ||||
Melanoma | MDX010-20 (NCT00094653) | ||||
Esophageal squamous cell carcinoma | CHECKMATE-648 (NCT03143153) | ||||
Malignant pleural mesothelioma | CHECKMATE-743 (NCT02899299) | ||||
NSCLC | CHECKMATE-9LA (NCT03215706) CHECKMATE-227 (NCT02477826) | ||||
Relatlimab-rmbw (Opdualag) | Bristol-Myers Squibb | LAG-3 | A human IgG4 monoclonal antibody | Melanoma | RELATIVITY-047 (NCT03470922) |